216144-45-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-Methylpiperazino)benzylamine is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure allows it to be a key component in the development of new drugs, particularly in the area of central nervous system medications.
Used in Chemical Research:
4-(4-Methylpiperazino)benzylamine is used as a research chemical for studying the properties and reactions of N-benzylpiperazines. This helps scientists understand the behavior of these compounds and their potential applications in various fields.
Used in Material Science:
4-(4-Methylpiperazino)benzylamine is used as a component in the development of new materials with specific properties. Its inclusion in the synthesis process can lead to the creation of materials with unique characteristics, such as improved stability or reactivity.
Used in Laboratory Settings:
4-(4-Methylpiperazino)benzylamine is used as a reagent in various laboratory experiments and procedures. Its presence in chemical reactions can provide valuable insights into the mechanisms and outcomes of these processes.

InChI:InChI=1/C12H19N3/c1-14-6-8-15(9-7-14)12-4-2-11(10-13)3-5-12/h2-5H,6-10,13H2,1H3

Upstream product

• 623-00-7 4-bromobenzenecarbonitrile 
• 109-01-3 1-methyl-piperazine 
• 1194-02-1 4-fluorobenzonitrile 
• 34334-28-6 4-(4-methylpiperazin-1-yl)benzonitrile 

Downstream Products

• 389601-85-8 N-[4-(4-methyl-piperazin-1-yl)-phenylmethyl]-3-(biphenyl-2-carbonylamino)-benzoic acid amide 
• 1033693-66-1 methyl 4-[2-[4-(4-methylpiperazin-1-yl)benzyl]amino-4-oxoquinazolin-3(4H)-yl]butanoate 
• 1451010-35-7 (4-(4-(1-(2-chloro-2-(4-chlorophenyl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl)phenyl)methanamine 
• 1451010-36-8 1-(2-chloro-2-(4-chlorophenyl)ethyl)-N-(4-(4-methylpiperazin-1-yl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1334717-47-3 7-chloro-2-ethyl-N-(4-(4-methylpiperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1612182-31-6 6-(2,3-dimethylphenyl)-4-N-{[4-(4-methylpiperazin-1-yl)phenyl]methyl}pyrimidine-2,4-diamine 
• 1033694-15-3 6-[4-(4-methylpiperazin-1-yl)benzyl]-5H-quinazolino[3,2-a]quinazoline-5,12(6H)-dione 
• 1033693-78-5 3-isobutyl-1-[4-(4-methylpiperazin-1-yl)benzyl]imidazo[2,1-b]quinazoline-2,5(1H,3H)-dione 
• 1033693-90-1 1'-[4-(4-methylpiperazin-1-yl)benzyl]-2'H-spiro[cyclopentane-1,3'-imidazo[2,1-b]quinazoline]-2',5'(1'H)-dione 
• 1169548-94-0 8-bromo-2-[({[4-(4-methylpiperazin-1-yl)phenyl]methyl}amino)methyl][1]benzofuro[3,2-d]pyrimidin-4(3H)-one 

Relevant academic research and scientific papers

Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents

A series of benzamide scaffolds were designed and synthesized by the thiazinone ring opening of PBTZ169, and N-benzyl 3,5-dinitrobenzamides were finally identified as anti-TB agents in this work. 3,5-Dinitrobenzamides D5, 6, 7, and 12 exhibit excellent in vitro activity against the drug susceptive Mycobacterium tuberculosis H37Rv strain (MIC: 0.0625 μg/mL) and two clinically isolated multidrug-resistant strains (MIC 0.016-0.125 μg/mL). Compound D6 displays acceptable safety and better pharmacokinetic profiles than PBTZ169, suggesting its promising potential to be a lead compound for future antitubercular drug discovery.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

An alternative synthetic approach for the synthesis of biologically relevant 1,4-disubstituted pyrazolo[3,4-d]pyrimidines

A versatile approach for the synthesis of 1,4-disubstituted pyrazolo[3,4-d]pyrimidines has been developed. Starting from commercially available allopurinol, TBAF mediated N1-functionalization and subsequent C4 nucleophilic substitution, under microwave assisted- or standard heating conditions, granted access to highly functionalized pyrazolo[3,4-d]pyrimidines of potential biological interest.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents

In an ongoing effort to develop new and potent antituberculosis agents, a second-generation series of nitrofuranyl amides was synthesized on the basis of the lead compound 5-nitrofuran-2-carboxylic acid 3,4-dimethoxybenzylamide. The primary design consideration was to improve the solubility and consequently the bioavailability of the series by the addition of hydrophilic rings to the benzyl and phenyl B ring core. The synthesis of 27 cyclic, secondary amine substituted phenyl and benzyl nitrofuranyl amides is described and their activity against Mycobacterium tuberculosis reported. The series showed a strong structure-activity relationship as the benzyl nitrofuranyl amides were significantly more active than similarly substituted phenyl nitrofuranyl amides. Para-substituted benzyl piperazines showed the most antituberculosis activity. Compounds in the series were subsequently selected for bioavailability and in vivo testing. This study led to the successful discovery of novel compounds with increased antituberculosis activity in vitro and a better understanding of the requisite pharmacological properties to advance this class.